Protalix Biotherapeutics Inc V.PLX.H

Primary Symbol: PLX

Healthcare Biotechnology

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.

NYSEAM:PLX - Post by User

Protalix Biotherapeutics Inc > stuck

<< Previous

Bullboard Posts

Next >>

Comment by Theconsortmanon Jun 10, 2019 2:51pm

79 Views

Post# 29812678

RE:RE:RE:RE:stuck

Oh I don't mean to "bash" just provide a sober view to balance out the "double, triple, to the moon n" nonsense spouted by Stockfy. Yes all juniors are facng a near imossible environment in terms of attracting new equity. The key question is do they have a strong enough situation to survive until investment comes back? Their only alternative is dilutive financings (stocks/warrants) and farm outs giving away chunks of upside. Hopefully this does not wash out all the potential upside of their new play. That is all. I see then trading 0.15-0.25 until we hopefully see an uptick in 2021.

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security